Demographic and Treatment Analysis of Periosteal Osteosarcoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals that surgery benefits periosteal osteosarcoma (PO) survival, while chemotherapy
Area Of Science
- Oncology
- Epidemiology
- Bone Cancers
Background
- Periosteal osteosarcoma (PO) is a rare bone cancer, comprising 1-6% of osteosarcomas.
- Limited epidemiological data exists for PO in the United States, with most literature based on single-center studies.
Purpose Of The Study
- To conduct the first comprehensive epidemiological assessment of periosteal osteosarcoma in the United States.
- To analyze demographic, disease, and treatment variables impacting survival in PO patients.
Main Methods
- Utilized the Surveillance, Epidemiology, and End Results (SEER) Program database.
- Identified patients with primary PO (ICD-O-3 code 9193/3).
- Performed Fisher's exact test for variable analysis and logrank analysis for 20-year cause-specific survival (20y CSS).
Main Results
- Fifty-four PO patients were identified; median age at diagnosis was 20-24 years.
- Surgery demonstrated a significant 20y CSS benefit (HR=0.08, p=0.040), while chemotherapy (CTX) did not (p=0.29).
- Appendicular PO showed longer mean survival (16.0 years) than axial PO (10.9 years); younger patients were more likely to have appendicular PO.
Conclusions
- Axial PO is linked to poorer 20y CSS compared to appendicular PO.
- Surgery alone was non-inferior to surgery plus CTX for both local and regional disease.
- The use of CTX in PO treatment warrants further investigation and may be best reserved for high-risk cases.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
